Collectively, the findings suggest that studies should examine whether the blockade of the oncogenic mutations of RAS, BRAF, or PI3K in certain types of cancer, such as CRC, restore EREG expression that mediates the activation of EGFR downstream signaling. The gene discussed is EGFR; the disease is cancer.